Abstract Details

Title Efficacy of Pharmacological Interventions in Lewy Body Dementia: An Updated Systematic Review and Network Meta-Analysis

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P8 - Poster Session 8 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-004

Objective To assess the efficacy of various pharmacological interventions for Lewy body dementia.

Background Lewy body dementia (LBD) causes progressive cognitive decline, muscle rigidity, tremors, and memory loss, severely impacting quality of life. This network meta-analysis (NMA) evaluates the efficacy of various pharmacological treatments for LBD, providing updated insights into optimal therapeutic approaches.

Design/Methods A systematic search of PubMed/MEDLINE, EMBASE, Scopus, Cochrane, and ClinicalTrials.gov was conducted to identify RCTs on LBD interventions up to June 2024. A Bayesian NMA evaluated drug effectiveness for LBD based on the Mini-Mental State Examination (MMSE) and the Neuropsychiatric Inventory (NPI). The analysis utilized the gemtc package in R, applying a random-effects model to account for heterogeneity and assessing convergence through trace plots and the Gelman-Rubin diagnostic, yielding posterior distributions for mean differences and 95% confidence intervals.

Results For the analysis of the primary outcomes, MMSE and NPI, 14 trials with a pooled population of 1,591 and 5 trials with a pooled population of 631 were included, respectively, resulting in 41 pairwise comparisons. Donepezil 5 mg showed a statistically significant mean difference (MD) of 2.2 (95% CI: 0.59 to 3.8), while Donepezil 10 mg had an MD of 1.8 (95% CI: 0.57 to 3.1), both with positive outcomes. In contrast, Exifone 600 mg had an MD of -6.4 (95% CI: -15 to 1.9). For NPI, Neflamapimod twice daily (BD) had an MD of -3.8 (95% CI: -12 to 4.5), which was not statistically significant. Bosutinib 100 mg showed higher incidences of serious adverse events (SAEs) and mortality, with odds ratios of 3.9 (95%: 1.3e^-11 to 2.4e²³) and 7.8e² (95%: 2.8e^-11 to 7.9e¹⁸), respectively.

Conclusions Donepezil 5 mg and 10 mg significantly improved MMSE scores in LBD patients. Neflamapimod (BD) showed non-significant improvement on the NPI scale, while Bosutinib 100 mg was linked to higher rates of SAEs and mortality.

Authors/Disclosures
Vinay Suresh, MBBS PRESENTER	Dr. Suresh has nothing to disclose.
Aman M. Bhonsale, MBBS (All India Institute of Medical Sciences, Nagpur)	Mr. Bhonsale has nothing to disclose.
Muneeb Ahmad Muneer (Allama Iqbal Medical College)	Mr. Muneer has nothing to disclose.
Poorvikha S	Poorvikha S has nothing to disclose.
Malavika Rudrakumar (St. John's medical college)	Miss Rudrakumar has nothing to disclose.
Marium Khan	Marium Khan has nothing to disclose.
Anmol Kaur (Lady Hardinge Medical College and Associated Hospitals)	Miss Kaur has nothing to disclose.
Mohammad Hassan Bin Ozair, MBBS	Mr. Bin Ozair has nothing to disclose.
Sakshi Sharma, Msc	No disclosure on file
Apoorva Vedula, MBBS	Miss Vedula has nothing to disclose.
Ishita Gupta (Amrita Institute of Medical Sciences Kochi)	Miss Gupta has nothing to disclose.
Ishita Lanjewar, MBBS	Dr. Lanjewar has nothing to disclose.
Kshitij Sonawale, MBBS	Dr. Sonawale has nothing to disclose.

��ɫ��

��ɫ��